Pharmaceuticals

YABAO PHARM.CORP

YABAO PHARM.CORP released FY2026 Q1 earnings on April 24 After-Market (BJT), actual revenue CNY 572.02 M, actual EPS CNY 0.1541

YABAO PHARM.CORP released FY2025 earnings on April 24 After-Market (BJT), actual revenue CNY 2.24 B, actual EPS CNY 0.4576

YABAO PHARM.CORP released FY2025 Q4 earnings on April 24 After-Market (BJT), actual revenue CNY 531.35 M, actual EPS CNY 0.1514

YABAO PHARM.CORP FY2026 Q1 Earnings Release on April 25 After-Market (BJT)

YABAO PHARM.CORP to Release FY2025 Annual Earnings on April 25, 2026 After-Market (BJT)

YABAO PHARM.CORP released FY2025 9 Months Earnings on October 24 After-Market (BJT), actual revenue CNY 1.709 B, actual EPS CNY 0.3062

YABAO PHARM.CORP released FY2025 Q3 earnings on October 24 After-Market (BJT), actual revenue CNY 569.3 M, actual EPS CNY 0.0581

YABAO PHARM.CORP to Release FY2025 Q3 Earnings on October 25 After-Market (BJT)

Yabao Pharm. Corp released FY2025 Q2 earnings on August 15 During-Market (BJT), actual revenue CNY 524.88 M, actual EPS CNY 0.0959

YABAO PHARM.CORP released FY2025 Semi-Annual Earnings on August 15 During-Market (BJT), Actual Revenue CNY 1.139 B, Actual EPS CNY 0.2483

YABAO PHARM.CORP to Release FY2025 Semi-Annual Earnings on August 16, 2025 (BJT)

Yabo Pharmaceutical Obtains 90 Million Yuan Loan for Stock Repurchase

Yabo Pharmaceutical's Subsidiary Obtains Consistency Evaluation Notice for Metoprolol Tartrate Tablets

Yabo Pharmaceutical Submits New Trademark Application

Yabo Pharmaceutical Reports Revenue and Net Profit Decline in Q1 2024

YABAO PHARM.CORP released FY2025 Q1 earnings on April 25 After-Market BJT, actual revenue CNY 614.53 M, actual EPS CNY 0.1522

YABAO PHARM.CORP released FY2024 earnings on April 25 After-Market BJT, actual revenue CNY 2.686 B, actual EPS CNY 0.3356

YABAO PHARM.CORP released FY2024 Q4 earnings on April 25 After-Market (BJT), actual revenue CNY 564.53 M, actual EPS CNY 0.0108

YABAO PHARM.CORP to Release FY2025 Q1 Earnings on April 26 After-Market BJT

YABAO PHARM.CORP to Release FY2024 Earnings Report on April 26 After-Market BJT

600351

YABAO PHARM.CORP announced that the company will repurchase shares through centralized bidding starting from May 16, 2025, with an expected amount of 50 million to 100 million yuan, aimed at reducing registered capital. As of October 31, a total of 8 million shares have been repurchased, accounting for 1.14% of the total share capital, with a total payment of 52.1519 million yuan, and the repurchase price range is 6.30 yuan/share to 6.65 yuan/share. The company will implement the repurchase at an opportune time during the repurchase period and disclose progress in a timely manner

Zhitong

YABAO PHARM.CORP: Cumulatively spent 52.1519 million yuan to repurchase 1.14% of shares

According to the Zhitong Finance APP, YABAO PHARM.CORP disclosed its third-quarter report for 2025. The company achieved revenue of 1.709 billion yuan in the first three quarters, a year-on-year decrease of 19.46%; the net profit attributable to the parent company was 215 million yuan, a year-on-year decrease of 8.44%; the net profit excluding non-recurring gains and losses was 197 million yuan, a year-on-year decrease of 9.03%; and the basic earnings per share were 0.3066 yuan

YABAO PHARM.CORP released its performance for the first three quarters, with a net profit attributable to the parent company of 215 million yuan, a year-on-year decrease of 8.44%

YABAO PHARM.CORP announced that its wholly-owned subsidiary Beijing YABAO Biopharmaceutical Co., Ltd. has obtained the drug registration certificate for Sitagliptin Metformin Extended-Release Tablets issued by the National Medical Products Administration. This medication is suitable for adult patients with type 2 diabetes, used in combination with Sitagliptin and Metformin. Sitagliptin Metformin Extended-Release Tablets were developed by MERCK SHARP DOHME and were approved for sale in the United States in 2012 under the brand name JANUMETXR®. It is expected that the sales of this drug in the domestic market will reach 921 million yuan in 2024

YABAO PHARM.CORP: Sitagliptin Metformin Extended-Release Tablets have obtained the drug registration certificate

YABAO PHARM.CORP disclosed the progress of its share repurchase. Since the shareholders' meeting approved the repurchase proposal on May 16, 2025, the company has repurchased a total of 6 million shares, accounting for 0.86% of the total share capital. The repurchase period is from May 16, 2025, to November 14, 2025, with an expected repurchase amount between 50 million and 100 million yuan, mainly used to reduce registered capital. The highest transaction price for the repurchase was 6.65 yuan/share, the lowest was 6.30 yuan/share, and the total payment amount was 38,878,040 yuan

YABAO PHARM.CORP disclosed the progress of its share repurchase, having repurchased a total of 6 million shares

YABAO PHARM.CORP's controlling shareholder, YABAO Investment, repurchased 13.65 million pledged shares in advance on September 26. After the pledge is lifted, the total pledged shares amount to 24.95 million, accounting for 26.46% of its holdings. YABAO Investment holds 94.3 million shares of the company, representing 13.47% of the total share capital. The company will closely monitor the pledge matters and disclose information in a timely manner

YABAO PHARM.CORP's controlling shareholder repurchased 13.65 million pledged shares in advance

YABAO PHARM.CORP's controlling shareholder, YABAO Investment, pledged 11.45 million shares on September 25 to repay debts, accounting for 12.14% of its holdings and 1.64% of the company's total share capital. The pledge period lasts until September 25, 2026. As of the announcement date, YABAO Investment holds 94.3 million shares in the company, with a total of 38.6 million shares pledged, representing 40.93% of its holdings and 5.51% of the company's total share capital. The company will closely monitor the pledge matters and disclose information in accordance with regulations

YABAO PHARM.CORP's controlling shareholder pledged 11.45 million shares to repay debts

YABAO PHARM.CORP recently received approval from the National Medical Products Administration for the clinical trial notification of the drug ZY-A002, with the number 2025LP02459. This drug will be used for confirmatory clinical trials of cough variant asthma in children, with indications including dispelling wind and promoting lung function, relieving spasms and stopping cough, primarily targeting symptoms such as coughing fits and throat itching

YABAO PHARM.CORP: ZY-A002 has received the drug clinical trial approval notice

YABAO PHARM.CORP announced the termination of the clinical research and development work for SY-009. After evaluation, it was decided to reasonably allocate R&D resources and focus on advantageous projects. At the same time, in accordance with accounting standards, the full amount of the R&D capitalization for this project will be fully provided for asset impairment, which is expected to reduce the total profit for the year 2025 by 55.7933 million yuan

YABAO PHARM.CORP terminates the clinical research and development work of SY-009

YABAO PHARM.CORP announced that its holding subsidiary Suzhou YABAO Pharmaceutical Research Co., Ltd. has received approval from the National Medical Products Administration for a new indication for the clinical trial of SY-005 injection for postoperative neurological dysfunction in brain glioma. SY-005 is an innovative recombinant protein that received clinical trial approval for sepsis indications in 2018 and is currently in the Phase II clinical trial stage

YABAO PHARM.CORP: SY-005 project new indication approved for clinical trials

According to the Zhitong Finance APP, YABAO PHARM.CORP disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 1.139 billion yuan, a year-on-year decrease of 21.08%; the net profit attributable to shareholders of the listed company was 174 million yuan, a year-on-year decrease of 2.99%; the net profit excluding non-recurring gains and losses was 160 million yuan, a year-on-year decrease of 1.69%; the basic earnings per share were 0.2483 yuan

YABAO PHARM.CORP released its semi-annual performance, with a net profit attributable to the parent company of 174 million yuan, a year-on-year decrease of 2.99%

YABAO PHARM.CORP(600351.SH)